Verana Health Stock

veranahealth.comHealthcare / Healthcare providers & servicesFounded: 2008Funding to Date: $297.95MM

Verana Health is a health technology company dedicated to assembling the largest clinical databases in medicine to empower physicians and accelerate research for patients.

Register for Details

For more details on financing and valuation for Verana Health, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Verana Health.

Register Today

Team

Management Team

Marc Berger JD
Senior Vice President & General Counsel
Miki Kapoor
Chief Executive Officer, President & Board Member
Chet Kumar
Vice President of Life Science, Commercial
Marie-Eve Piche
Chief Financial Officer
Nitin Karandikar
Senior Vice President, Technology

Board Members

Julie Sunderland
Biomatics Capital
Steven Schwartz MD
Krishna Yeshwant MD
GV
Miki Kapoor
Verana Health
David Parke MD
Leslie Bottorff
GE Ventures
Catherine Rydell

Other companies like Verana Health in the Healthcare providers & services sector

Sector
Last Round Est. Valuation
$648.94MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$1.39B
Sector
Last Round Est. Valuation
$5.7B
Sector
Last Round Est. Valuation
$37.8MM
Sector
Last Round Est. Valuation
$1.81B
Sector
Last Round Est. Valuation
$2.18B
Sector
Last Round Est. Valuation
$3.52B
Sector
Last Round Est. Valuation
$1.53B

News Highlights

With $30M from GV, DigiSight rebrands as Verana Health, pivots into data science
Tele-ophthalmology company DigiSight — now called Verana Health — has a new name, a new mission, a new CEO, and $30 million dollars in new funding led by Alphabet subsidiary GV (formerly Google Ventures). Additional contributors to the round include Biomatics Capital, Brook Byers (founder of Kleiner, Perkins, Caufield & Byers), GE Ventures, and Lagunita Biosciences, all existing investors.
Updated on: Sep 22, 2023